US stock market offers worst returns for next decade
US stocks are due to deliver the worst returns to equity investors globally over the next 10 years.
It's undoubtedly been an interesting time for global investment markets. Following a strong 2017 for many growth assets, 2018 has seen a return to more challenging conditions. Confirmation of the continued upward path for interest rates in the US, combined with escalating trade tensions and potential geopolitical threats has resulted in volatility not seen since early 2016.
In addition, we've faced ongoing Brexit negotiations and concerns over the political outlook in Italy, which at its heart, questions the sustainability of the Eurozone. This comes just as the European Central Bank slows its stimulus program, ensuring there is no shortage of uncertainty to be navigated by investors.
Against this backdrop, equity markets have, nonetheless, managed to post impressive medium-term returns. Emerging markets have borne the brunt of the recent volatility yet have still delivered double digit gains over the last twelve months. Returns from Japanese and US equities over the past twelve months have also been strong, especially the technology sector, with US investors further buoyed by corporate tax rate cuts and solid earnings results.
Changes in interest rate and inflation expectations have generally resulted in much more muted returns from key defensive assets like government bonds and other interest rate-sensitive asset classes including listed property and listed infrastructure, with the latter experiencing significant volatility.
We reiterate our perpetual message that it's incredibly hard to know how the economic and political events around the world will play out. We are especially sceptical of anyone trying to position for these events in advance as it rarely adds value to portfolio returns. The bigger opportunity, to our way of thinking, is to assess valuations in both equity and bond markets in a world where investor sentiment appears complacent.
In undertaking this analysis, we can see disparate expected returns across the investment universe, offering an opportunity to reduce the risk of loss as major markets return to what they are worth, over time. It's difficult to predict the timing and catalyst for any strength or weakness, of course, and while we are not forecasting some imminent or catastrophic decline, we need to be prudently positioned and ensure we remain fundamentally diversified.
US due to deliver worst equity returns globally
Positive sentiment continues to surround the outlook for US growth, with a booming technology sector and corporate tax rate cuts influencing demand. This has exacerbated our cautious stance, with the asset class now offering negligible expected returns after inflation, on our valuation analysis.
While acknowledging the structural improvement in fundamentals brought about by the lower corporate tax rate, we believe that much of the good news relating to the strengthening US economy is now more than priced into the market, with US shares now trading well ahead of our fair value estimates. This sees an elevated risk of a permanent loss of capital from these levels.
An exception to this is the US healthcare sector which has been plagued by uncertainty over the outlook for healthcare regulation, given the Trump administration's attempts to repeal Obamacare and reform pharmaceutical drug pricing policy.
While delays and a softening of this agenda have tempered negative sentiment, resulting in a strong start for the sector in 2018, a valuation opportunity nonetheless remains. Further, the majority of companies that make up the US healthcare index, by market capitalisation, such as Johnson & Johnson, Pfizer and Bristol-Myers Squibb, are "Wide" or "Narrow" moat-rated by Morningstar Equity Research, which we believe may highlight the sustainability of earnings in the sector.
More from Morningstar
• Make better investment decisions with Morningstar Premium | Free 4-week trial
Dan Kemp is Chief Investment Officer, Morningstar Investment Management EMEA
© 2018 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/s/fsg.pdf. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782 ("ASXO"). The article is current as at date of publication.
